164 related articles for article (PubMed ID: 12138687)
21. [Idiopathic thrombocytopenic purpura associated with mantle cell lymphoma showing an increase in the platelet count receiving anti-CD20 antibody rituximab].
Kawachi Y; Ide M; Uchida T; Setsu K
Rinsho Ketsueki; 2003 Jan; 44(1):31-3. PubMed ID: 12649836
[TBL] [Abstract][Full Text] [Related]
22. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
[TBL] [Abstract][Full Text] [Related]
23. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
[TBL] [Abstract][Full Text] [Related]
24. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
Zhu YC; Wang W; Zhou YH; Wang XM; Wang X; Wang YL; Sun GZ; Hou M
Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
[TBL] [Abstract][Full Text] [Related]
25. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
26. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood.
Taube T; Schmid H; Reinhard H; von Stackelberg A; Overberg US
Haematologica; 2005 Feb; 90(2):281-3. PubMed ID: 15710595
[TBL] [Abstract][Full Text] [Related]
27. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
Li Y; Wang XM; Mao M; Zhang XY; Fu L; Ai HM; Zhang LX
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
[TBL] [Abstract][Full Text] [Related]
28. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
[TBL] [Abstract][Full Text] [Related]
29. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
Thude H; Gruhn B; Werner U; Schorner U; Häfer R; Zintl F; Barz D
Acta Haematol; 2004; 111(4):221-4. PubMed ID: 15153715
[TBL] [Abstract][Full Text] [Related]
30. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment.
Wang J; Wiley JM; Luddy R; Greenberg J; Feuerstein MA; Bussel JB
J Pediatr; 2005 Feb; 146(2):217-21. PubMed ID: 15689912
[TBL] [Abstract][Full Text] [Related]
31. [Effective treatment with rituximab in a patient with refractory idiopathic thrombocytopenic purpura].
Tanai C; Iki S; Nakahara F; Iijima K; Usuki K; Kuwana M; Urabe A
Rinsho Ketsueki; 2004 Nov; 45(11):1181-6. PubMed ID: 15609684
[TBL] [Abstract][Full Text] [Related]
32. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
Aggarwal A; Catlett JP
South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura.
Julia A; Kovaleva L; Loria S; Alberca I; Hernandez F; Sandoval V; Sierra J; Vidaller A; Ayguasanosa J; Carretero M
Transfus Med; 2009 Oct; 19(5):260-8. PubMed ID: 19747289
[TBL] [Abstract][Full Text] [Related]
34. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases.
Mantadakis E; Danilatou V; Stiakaki E; Kalmanti M
Am J Hematol; 2004 Nov; 77(3):303-10. PubMed ID: 15495242
[TBL] [Abstract][Full Text] [Related]
35. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
Saleh MN; Gutheil J; Moore M; Bunch PW; Butler J; Kunkel L; Grillo-López AJ; LoBuglio AF
Semin Oncol; 2000 Dec; 27(6 Suppl 12):99-103. PubMed ID: 11226008
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of amifostine in treating patients with idiopathic thrombocytopenia purpura.
Fan H; Zhu HL; Li SX; Lu XC; Zhai B; Guo B; Yao SQ; Liu Y
Cell Biochem Biophys; 2011 Jan; 59(1):7-12. PubMed ID: 21104159
[TBL] [Abstract][Full Text] [Related]
37. The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab.
Kuwana M; Iki S; Urabe A
Am J Hematol; 2007 Sep; 82(9):846-8. PubMed ID: 17506067
[TBL] [Abstract][Full Text] [Related]
38. Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura.
Clausen MR; Segel E; Brandsborg M; d'Amore F
Eur J Haematol; 2011 Mar; 86(3):256-9. PubMed ID: 21166717
[TBL] [Abstract][Full Text] [Related]
39. Critical issues of current and future developments in the treatment of immune thrombocytopenic purpura.
Koene HR
Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):703-5. PubMed ID: 16933273
[TBL] [Abstract][Full Text] [Related]
40. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura.
Moschovi M; Trimis G; Pergantou H; Platokouki H; Vrachnou E; Tzortzatou-Stathopoulou F
J Paediatr Child Health; 2005 Jul; 41(7):384-6. PubMed ID: 16014149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
